Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of Palvella Therapeutics, Inc. patents

List of Palvella Therapeutics, Inc. patents

List of Gebr. Heller patents

List of ZAP (motor company) patents

List of U-Systems patents

List of SBIR/STTR awards granted to Lexeo Therapeutics

List of companies in Better Tomorrow Ventures's investment portfolio

Patents where

Current Assignee

Name

is

Palvella Therapeutics, Inc.

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 11617742 Methods of treating keratin hyperproliferation disorders using mTOR inhibitors	Patent 11617742 was granted and assigned to Palvella Therapeutics, Inc. on April, 2023 by the United States Patent and Trademark Office.	Palvella Therapeutics, Inc.	Palvella Therapeutics, Inc.		United States Patent and Trademark Office	11617742	April 4, 2023
	‌ US Patent 11000513 Anhydrous compositions of mTOR inhibitors and methods of use	Patent 11000513 was granted and assigned to Palvella Therapeutics, Inc. on May, 2021 by the United States Patent and Trademark Office.	Palvella Therapeutics, Inc.	Palvella Therapeutics, Inc.		United States Patent and Trademark Office	11000513	May 11, 2021
	‌ US Patent 10172789 Compositions for transdermal delivery of mTOR inhibitors	Patent 10172789 was granted and assigned to Palvella Therapeutics, Inc. on January, 2019 by the United States Patent and Trademark Office.	Palvella Therapeutics, Inc.	Palvella Therapeutics, Inc.		United States Patent and Trademark Office	10172789	January 8, 2019
	‌ US Patent 10722499 Anyhydrous compositions of mTOR inhibitors and methods of use		Palvella Therapeutics, Inc.	Palvella Therapeutics, Inc.		United States Patent and Trademark Office	10722499	July 28, 2020
	‌ US Patent 9855252 Methods of treating keratin hyperproliferation disorders using mTOR inhibitors	Patent 9855252 was granted and assigned to Palvella Therapeutics, Inc. on January, 2018 by the United States Patent and Trademark Office.	Palvella Therapeutics, Inc.	Palvella Therapeutics, Inc.		United States Patent and Trademark Office	9855252	January 2, 2018
	‌ US Patent 11135204 Anhydrous compositions of mTOR inhibitors and methods of use	Patent 11135204 was granted and assigned to Palvella Therapeutics, Inc. on October, 2021 by the United States Patent and Trademark Office.	Palvella Therapeutics, Inc.	Palvella Therapeutics, Inc.		United States Patent and Trademark Office	11135204	October 5, 2021
	‌ US Patent 11679101 Anhydrous compositions of mTOR inhibitors and methods of use		Palvella Therapeutics, Inc.	Palvella Therapeutics, Inc.		United States Patent and Trademark Office	11679101	June 20, 2023

7 results

0 selected

7 results

0 selected